Evidence map›Paper›PMID 23208492›Full record

ArticleOncogene2014

In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated β1 integrin and induction of FAK/PI3K/Akt motility signaling.

B Casar, I Rimann, H Kato, S J Shattil, J P Quigley, E I Deryugina

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04708444 (Prognostic Value of CD318 in Acute Myeloid Leukemia Patients at Assiut University Hospital), which is not on this map. Cited by 71 papers.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04708444 unknown statusnot on this mapstarted 2021, after this paper: background citation

Prognostic Value of CD318 in Acute Myeloid Leukemia Patients at Assiut University Hospital

TypeobservationalSponsorShimaa Arafa IbrahimRan2021 to 2023Enrolled100ConditionsAcute Myeloid LeukemiaArmsCD318
3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 132 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  16. Antibody-Based Approaches to Target Pancreatic Tumours.Antibodies (Basel, Switzerland) · 2022
    Review
  17. Article
  18. Article
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

B CasarThe Cell Biology Department, The Scripps Research Institute, La Jolla, CA, USA.
I RimannThe Cell Biology Department, The Scripps Research Institute, La Jolla, CA, USA.
H KatoDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
S J Shattil1] Department of Medicine, University of California San Diego, La Jolla, CA, USA [2] Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
J P QuigleyThe Cell Biology Department, The Scripps Research Institute, La Jolla, CA, USA.
E I DeryuginaThe Cell Biology Department, The Scripps Research Institute, La Jolla, CA, USA.
Scripps Research Institute · USUniversity of California, San Diego · US

Funding

TYROSINE KINASE C-ABL AND BCR-ABL IN INTEGRIN DEPENDENT SIGNALINGP01HL057900 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SHATTIL, SANFORD J · 1997 to 2012
$17.4M
SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE (UL1)UL1RR025774 · NCRR · SCRIPPS RESEARCH INSTITUTE, THE · PI TOPOL, ERIC JEFFREY · 2008 to 2011
$16.3M
Discoveries at the Crossroads of Integrin and Inflammatory Signaling in PlateletsR01HL056595 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SHATTIL, SANFORD J · 1996 to 2020
$7.5M
Transmembrane Proteins Involved in Human Tumor ExpansionR01CA105412 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI QUIGLEY, JAMES P · 2004 to 2020
$5.8M
A Cellular and Molecular Analysis of the Intravasation Step in Tumor MetastasisR01CA129484 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI QUIGLEY, JAMES P · 2008 to 2012
$2.3M
Role of Inflammatory Neutrophils and their Unique MMP-9 in Tumor ProgressionR01CA157792 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI DERYUGINA, ELENA I · 2012 to 2016
$1.9M
NCI NIH HHS R01 CA 105412NCI NIH HHS R01 CA105412NCI NIH HHS R01 CA 129484NCI NIH HHS R01 CA129484NCI NIH HHS R01 CA157792NCRR NIH HHS RR 025774NCRR NIH HHS UL1 RR025774NHLBI NIH HHS HL56595NHLBI NIH HHS HL57900NHLBI NIH HHS P01 HL057900NHLBI NIH HHS R01 HL056595
6 · The paper itself

Abstract

Specific cleavage of the transmembrane molecule, CUB domain-containing protein-1 (CDCP1), by plasmin-like serine proteases induces outside-in signal transduction that facilitates early stages of spontaneous metastasis leading to tumor cell intravasation, namely cell escape from the primary tumor, stromal invasion and transendothelial migration. We identified active β1 integrin as a biochemical and functional partner of the membrane-retained 70-kDa CDCP1 fragment, newly generated from its full-length 135-kDa precursor though proteolytic cleavage by serine proteases. Both in cell cultures and in live animals, active β1 integrin complexed preferentially with functionally activated, phosphorylated 70-kDa CDCP1. Complexing of β1 integrin the 70-kDa with CDCP1 fragment induced intracellular phosphorylation signaling, involving focal adhesion kinase-1 (FAK) and PI3 kinase (PI3K)-dependent Akt activation. Thus, inhibition of FAK/PI3K activities by specific inhibitors as well as short-hairpin RNA downregulation of β1 integrin significantly reduced FAK/Akt phosphorylation under conditions where CDCP1 was processed by serine proteases, indicating that FAK/PI3K/Akt pathway operates downstream of cleaved CDCP1 complexed with β1 integrin. Furthermore, this complex-dependent signaling correlated positively with high levels of tumor cell intravasation and dissemination. Correspondingly, abrogation in vivo of CDCP1 cleavage either by unique cleavage-blocking monoclonal antibody 10-D7 or by inhibition of proteolytic activity of plasmin-like serine proteases with aprotinin prevented β1 integrin/CDCP1 complexing and downstream FAK/Akt signaling concomitant with significant reduction of stromal invasion and spontaneous metastasis. Therefore, β1 integrin appears to serve as a motility-regulating partner mediating cross-talk between proteolytically cleaved, membrane-retained CDCP1 and members of FAK/PI3K/Akt pathway. This CDCP1 cleavage-induced signaling cascade constitutes a unique mechanism, independent of extracellular matrix remodeling, whereby a proteolytically cleaved CDCP1 regulates in vivo locomotion and metastasis of tumor cells through β1 integrin partnering. Our findings indicate that CDCP1 cleavage, occurring at the apex of a β1 integrin/FAK/PI3K/Akt signaling cascade, may represent a therapeutic target for CDCP1-positive cancers.

Indexed as

AnimalsAntigens, CDAntigens, NeoplasmCell Adhesion MoleculesCell Line, TumorCell MovementChick EmbryoEndothelial CellsFocal Adhesion Kinase 1HumansIntegrin beta1MaleMiceNeoplasm InvasivenessNeoplasm MetastasisNeoplasm ProteinsAntigens, CDAntigens, NeoplasmCDCP1 protein, humanCell Adhesion MoleculesFocal Adhesion Kinase 1Integrin beta1Neoplasm ProteinsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSerine Proteases

Identifiers

PMID23208492
PMCPMC3931462
OpenAlexW2004909339

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.